SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

被引：61

作者：

Advani, Anjali S. ^{[1
]}

McDonough, Shannon ^{[2
]}

Coutre, Steven ^{[3
]}

Wood, Brent ^{[4
]}

Radich, Jerald ^{[5
]}

Mims, Martha ^{[6
]}

O'Donnell, Margaret ^{[7
]}

Elkins, Stephanie ^{[8
]}

Becker, Michael ^{[9
]}

Othus, Megan ^{[2
]}

Appelbaum, Frederick R. ^{[5
]}

机构：

[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA

[2] Fred Hutchinson Canc Ctr, SWOG Stat Ctr, Seattle, WA USA

[3] Stanford Univ, Sch Med, Stanford, CA 94305 USA

[4] Seattle Canc Care Alliance, Seattle, WA USA

[5] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[6] Baylor Med Ctr, Houston, TX USA

[7] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[8] Univ Mississippi, Jackson, MS 39216 USA

[9] Univ Rochester, Med Ctr, Rochester, NY 14642 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 165卷 / 04期

关键词：

epratuzumab; Treatment; acute lymphocytic leukaemia; CD22; relapse; ACUTE LYMPHOBLASTIC-LEUKEMIA; SOUTHWEST-ONCOLOGY-GROUP; RELAPSE;

D O I：

10.1111/bjh.12778

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody against CD22, to the combination of clofarabine and cytarabine in adults with relapsed/refractory pre-B ALL. The response rate [complete remission and complete remission with incomplete count recovery] was 52%, significantly higher than our previous trial with clofarabine/cytarabine alone, where the response rate was 17%. This result is encouraging and suggests a potential benefit to adding epratuzumab to chemotherapy for ALL; however, a randomized trial will be needed to answer this question.

引用

页码：504 / 509

页数：6

共 12 条

[1] Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia [J].

Advani, Anjali S. ;

Gundacker, Holly M. ;

Sala-Torra, Olga ;

Radich, Jerald P. ;

Lai, Raymond ;

Slovak, Marilyn L. ;

Lancet, Jeffrey E. ;

Coutre, Steve E. ;

Stuart, Robert K. ;

Mims, Martha P. ;

Stiff, Patrick J. ;

Appelbaum, Frederick R. .

BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (05) :430-434

[2]

BOUE DR, 1988, BLOOD, V71, P1480

[3] Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study [J].

Fielding, Adele K. ;

Richards, Susan M. ;

Chopra, Rajesh ;

Lazarus, Hillard M. ;

Litzow, Mark R. ;

Buck, Georgina ;

Durrant, I. Jill ;

Luger, Selina M. ;

Marks, David I. ;

Franklin, Ian M. ;

McMillan, Andrew K. ;

Tallman, Martin S. ;

Rowe, Jacob M. ;

Goldstone, Anthony H. .

BLOOD, 2007, 109 (03) :944-950

[4] Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro [J].

Herrera, L ;

Farah, RA ;

Pellegrini, VA ;

Aquino, DB ;

Sandler, ES ;

Buchanan, GR ;

Vitetta, ES .

LEUKEMIA, 2000, 14 (05) :853-858

[5]

HOELZER D, 1991, SEMIN HEMATOL, V28, P84

[6]

Hoelzer D., 2002, LEUKEMIA, P621

[7] Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study [J].

Kantarjian, Hagop ;

Thomas, Deborah ;

Jorgensen, Jeffrey ;

Jabbour, Elias ;

Kebriaei, Partow ;

Rytting, Michael ;

York, Sergernne ;

Ravandi, Farhad ;

Kwari, Monica ;

Faderl, Stefan ;

Rios, Mary Beth ;

Cortes, Jorge ;

Fayad, Luis ;

Tarnai, Robert ;

Wang, Sa A. ;

Champlin, Richard ;

Advani, Anjali ;

O'Brien, Susan .

LANCET ONCOLOGY, 2012, 13 (04) :403-411

[8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[9] Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study [J].

Pullarkat, Vinod ;

Slovak, Marilyn L. ;

Kopecky, Kenneth J. ;

Forman, Stephen J. ;

Appelbaum, Frederick R. .

BLOOD, 2008, 111 (05) :2563-2572

[10]

Raetz E. A., 2011, REINDUCTION CHEMOIMM

← 1 2 →